对于需要高剂量上腺素的败血性休克患者的多素B血输:多中心前性队列研究
Yu Kawazoe1, Kyohei Miyamoto2, Noriko Miyagawa3
1Department of Emergency and Critical Care Medicine, Tohoku University Hospital, Sendai, Japan.
Critical care explorations
|September 22, 2025
概括
聚米辛B血输液 (PMX-HP) 在败血性休克患者中没有改善28天死亡率. 然而,PMX-HP确实增加了平均动脉压,并在入院的最初几个小时减少了血管压缩剂的使用.
科学领域:
- 关键护理医学 关键护理医学
- 腎臟病學 (nephrology) 是一種醫學.
- 免疫学 免疫学 免疫学
背景情况:
- 败血症是一种危及生命的器官功能障碍,是由宿主对感染反应失调引起的.
- 聚米辛B血 perfusion (PMX-HP) 是一种体外治疗,旨在在败血症期间去除内毒素.
- 在败血症中PMX-HP的临床疗效仍然不完全理解.
研究的目的:
- 调查PMX-HP与重症监护室 (ICU) 感染败血症休克患者的临床结果之间的关联.
- 评估PMX-HP对死亡率,血液动力学参数和血管压缩剂要求的影响.
主要方法:
- 一项多中心前性队列研究,涉及日本20个ICU (2020-2022).
- 包括患有败血性休克的患者,需要高剂量的诺亚上腺素 (≥0.2μg/kg/min).
- 对接受PMX-HP和不接受PMX-HP的患者之间的结果进行比较,重点关注28天死亡率,血液动力学变化和血管压缩剂的使用.
主要成果:
- 在309名患者中,82人接受了PMX-HP. 基线特征在各组之间是相似的.
- 在28天死亡率 (17.1%与18.9%,p=0.71) 或90天死亡率 (23.5%与27.1%,p=0.62) 中没有显著差异.
- 在入院后8至32小时内,PMX-HP组的平均动脉压较高,血管压缩剂使用减少,但没有ICU的日数较少.
结论:
- 在这种感染性休克队列中,PMX-HP与28天死亡率的改善无关.
- PMX-HP在血液动力学支持方面表现出暂时的益处,增加了MAP并降低了血管压缩剂的需求.
- 根据这些发现,建议仔细考虑和调整PMX-HP疗法.
相关概念视频
01:25Extracorporeal Removal of Drugs: Hemoperfusion and Hemofiltration
192
Hemoperfusion and hemofiltration are critical techniques in medical treatments to eliminate accumulated drugs, metabolites, and electrolytes from the bloodstream. These methods are particularly vital in cases of accidental poisoning and drug overdose.Hemoperfusion involves passing blood through an adsorbent material to remove unwanted substances. The main adsorbents used in hemoperfusion include activated charcoal and Amberlite resins. Activated charcoal can adsorb both polar and nonpolar...
192
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
271
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
271
01:24Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
233
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
233
01:15Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
238
Gentamicin, an aminoglycoside antibiotic, is commonly administered via intermittent intravenous infusion to treat severe infections. An intermittent one-hour infusion of gentamicin, administered at eight-hour intervals, allows for precise control of plasma drug concentrations, minimizing toxicity while ensuring therapeutic efficacy. Pharmacokinetic principles govern the dynamics of plasma concentrations and can be mathematically described using specific equations.The plasma drug concentration...
238
01:28Acute Pyelonephritis II: Diagnostic Studies and Management
321
Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
321